en · de · es · fr · pt
cjc-1295-notes.peptides4962.com › Faq › Receptor Action And Pharmacokinetics — Common Mistakes

Receptor Action And Pharmacokinetics — Common Mistakes

By Editorial Desk · published 2025-11-07 · last reviewed 2025-12-13 · Faq

If you have been reading about Albumin conjugation and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Updated 2025-12-13. Numbers and descriptions here follow the published literature rather than marketing material.

Receptor Action and Pharmacokinetics

Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.

CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.

Structure And Receptor Pharmacology

Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.

CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.

Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.

Cjc-1295 at a glance

PropertyValueNotes
Primary targetGHRH receptorG-protein-coupled receptor on pituitary somatotrophs
Half-life, long-acting formSeveral daysExtended by covalent albumin binding
Half-life, short formAbout 30 minutesCleared rapidly by peptidases and kidneys
Route in studiesSubcutaneous injectionUsed in the published human trials
Main measured effectRise in GH and IGF-1Surrogate markers rather than clinical endpoints

Mechanism and Pharmacokinetics

The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.

Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.

Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.

Related pages on this site

Molecular Background and Naming

The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.

CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.

CJC-1295 Structure And Mechanism

The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.

Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.

Background from the literature

A lateral flow test (LFT), is an assay also known as a lateral flow immunochromatographic test (ICT). It is a simple device intended to detect the presence of a target substance in a liquid sample without the need for specialized and costly equipment. LFTs are widely used in medical diagnostics in the home, at the point of care, and in the laboratory. For instance, the home pregnancy test is an LFT that detects a specific hormone. These tests are simple and economical and generally show results in around five to thirty minutes. Many lab-based applications increase the sensitivity of simple LFTs by employing additional dedicated equipment. Many LFTs are called rapid diagnostic tests (RDTs), though this term also includes other formats such as the vertical-flow tests. LFTs operate on the same principles of affinity chromatography as the enzyme-linked immunosorbent assays (ELISA). In essence, these tests run the liquid sample along the surface of a pad with reactive molecules that show a visual positive or negative result. The pads are based on a series of capillary beds, such as pieces of porous paper, microstructured polymer, or sintered polymer. Each of these pads has the capacity to transport fluid (e.g., urine, blood, saliva) spontaneously. The sample pad acts as a sponge and holds an excess of sample fluid. Once soaked, the fluid flows to the second conjugate pad in which the manufacturer has stored freeze dried bio-active particles called conjugates (see below) in a salt–sugar matrix.

The safety of a medical product concerns the medical risk to the subject, usually assessed in a clinical trial by laboratory tests (including clinical chemistry and haematology), vital signs, clinical adverse events (diseases, signs and symptoms), and other special safety tests (e.g. ECGs, ophthalmology). The tolerability of the medical product represents the degree to which overt adverse effects can be tolerated by the subject. (ICH E9) Screening trials

== Genetics == Chinese landraces were found to have a slightly higher genetic diversity than inbred lines by Li et al., 2010. Specific locus amplified fragment sequencing (SLAF-seq) has been used by Han et al., 2015 to study the genetic history of the domestication process, perform genome-wide association studies (GWAS) of agronomically relevant traits, and produce high-density linkage maps. An SNP array was developed by Song et al., 2013 and has been used for research and breeding; the same team applied their array in Song et al., 2015 against the USDA Soybean Germplasm Collection and obtained mapping data that are expected to yield association mapping data for such traits. Rpp1-R1 is a resistance gene against soybean rust. Rpp1-R1 is an R gene (NB-LRR) providing resistance against the rust pathogen Phakopsora pachyrhizi. Its synthesis product includes a ULP1 protease. Qijian et al., 2017 provides the SoySNP50K gene array.

atomic number (Z) Also proton number. The number of protons found in the nucleus of an atom of a given chemical element. It is identical to the charge number of the nucleus and is used in the periodic table to uniquely identify each chemical element.

Vivien Jess. Learning Centre Manager, Education Training Service. For services to Defence and to the community in Northern Ireland. Dr Terry Martin John. Lately General Practitioner, The Firs Medical Centre, London Borough of Waltham Forest and lately Chair of International Committee, British Medical Association. For services to Medicine. Frances Barbara Johnson. Learning Support Assistant, Dame Tipping Church of England Primary School, Romford, London Borough of Havering. For services to Education. Louis Connor Johnson. For services to the community in Wolverhampton, West Midlands. Hilary Johnston. Founder, Cwtch Baby Bank. For services to Mothers and Babies in South East Wales. Monica Ann Johnston. Admission/Discharge Co-ordinator, Neurosciences, Belfast Health and Social Care. For services to Nursing and to the community in Northern Ireland. Anne Jones. For services to the community in Neston, Cheshire. Patricia Ellen Jones. For services to the community in Nailsworth, Gloucestershire. Sundeep Kaur. Director, United Sikhs. For services to the community in the West Midlands during Covid-19. Lisa Michelle Kay. For charitable services to Ukrainian Refugees and to the community in Solihull, West Midlands. Coral June Kelham. For services to the community in Barrow upon Soar, Leicestershire. Anne Marie Kelly. Lately Regional Office Manager, Northern Ireland Organ Donor Service. For services to Organ Donation and Transplantation in Northern Ireland. Richard Kennell. Chief Executive Officer, SOFEA. For services to Social Inclusion and to Alleviating Food Poverty.

Sources: en.wikipedia.org

Further detail

=== By choosing the best age === Because of the intrinsic uncertainties within the three yield U-Pb ages (207Pb/235U, 206Pb/238U and 207Pb/206Pb), the age at ~1.4 Ga has the poorest resolution. An overall consensus for age with higher accuracy is to adopt:

=== Fleischmann–Pons experiment === The most famous cold fusion claims were made by Stanley Pons and Martin Fleischmann in 1989. After a brief period of interest by the wider scientific community, their reports were called into question by nuclear physicists. Pons and Fleischmann never retracted their claims, but moved their research program from the US to France after the controversy erupted.

=== Filming === On 4 April 2019, a photoshoot featuring Rajinikanth was held at a studio in Chennai. The stills which were leaked onto the internet and showed the actor in a cop avatar. Principal photography for the film began on 10 April in Mumbai. Images featuring Rajinikanth, Nivetha Thomas and Yogi Babu were also leaked onto the internet. On 3 May 2019, filming was suspended following reports of friction with college students at a campus that was being used as a location, and it later resumed. The film's first schedule was completed on 15 May. The film's second schedule resumed on 29 May and ended on 30 June. Suniel Shetty joined the film's second schedule. On 5 June 2019, a video from the filming location was unofficially posted on the internet despite high security on the sets. The filmmakers reported a similar incident during the filming on the last week of June 2019. The team shifted location from Mumbai to Delhi, citing heavy rains. It was reported filming would finish in late August 2019. After completing the film's second schedule, the makers took a 10-day-long break and filming resumed on 10 July 2019. On 25 July, Murugadoss shared images from the film showing Rajinikanth holding a sword and walking through a cloud of dust in a policeman's uniform; another image showed him looking happier and wearing a light blue suit. The final schedule of the film took place on 19 August 2019 in Jaipur, where two action sequences were filmed. On 11 October 2019, the makers announced they had completed filming.

== Clinical significance == Human HGF plasmid DNA therapy of cardiomyocytes is being examined as a potential treatment for coronary artery disease as well as treatment for the damage that occurs to the heart after myocardial infarction. As well as the well-characterised effects of HGF on epithelial cells, endothelial cells and haemopoietic progenitor cells, HGF also regulates the chemotaxis of T cells into heart tissue. Binding of HGF by c-Met, expressed on T cells, causes the upregulation of c-Met, CXCR3, and CCR4 which in turn imbues them with the ability to migrate into heart tissue. HGF also promotes angiogenesis in ischemia injury. HGF may further play a role as an indicator for prognosis of chronicity for Chikungunya virus induced arthralgia. High HGF levels correlate with high rates of recovery. Excessive local expression of HGF in the breasts has been implicated in macromastia. HGF is also importantly involved in normal mammary gland development. HGF has been implicated in a variety of cancers, including of the lungs, pancreas, thyroid, colon, and breast. Increased expression of HGF has been associated with the enhanced and scarless wound healing capabilities of fibroblast cells isolated from the oral mucosa tissue.

Sources: en.wikipedia.org

Background from the literature

Researchers have developed a method to efficiently produce substantial quantities of heterologous viral glycoproteins within the allantoic cavity of embryonated chicken eggs. This technique utilizes a Sendai virus minigenome as a vector to express soluble variants of specific proteins, notably the human respiratory syncytial virus (HRSV) and human metapneumovirus (HMPV) fusion (F) proteins. These proteins are engineered without their transmembrane and cytoplasmic domains, facilitating their solubility. Overview of the methodology:

Psychopathology is the study of mental illness, particularly of severe disorders. Informed heavily by both psychology and neurology, its purpose is to classify mental illness, elucidate its underlying causes, and guide clinical psychiatric treatment accordingly. Although diagnosis and classification of mental norms and disorders is largely the purview of psychiatry—the results of which are guidelines such as the Diagnostic and Statistical Manual of Mental Disorders, which attempt to classify mental disease mostly on behavioural evidence, though not without controversy—the field is also heavily, and increasingly, informed upon by neuroscience and other of the biological cognitive sciences. Mental or social disorders or behaviours seen as generally unhealthy or excessive in a given individual, to the point where they cause harm or severe disruption to the person's lifestyle, are often called "pathological" (e.g., pathological gambling or pathological liar).

=== Frank H. Field and Joe L. Franklin Award for Outstanding Achievement in Mass Spectrometry (since 1985) === 2021 Veronica M. Bierbaum 2020 Kimberly A. Prather 2019 Jennifer S. Brodbelt 2018 Carol Vivien Robinson 2017 Vicki H. Wysocki 2015 Hilkka I. Kenttämaa 2010 Catherine E. Costello 2008 Catherine C. Fenselau 1990 Marjorie G. Horning

== Use and effects == 4-HO-EPT was not included nor mentioned in Alexander Shulgin's book TiHKAL (Tryptamines I Have Known and Loved). Subsequently, however, an assumed prodrug of 4-HO-EPT, 4-AcO-EPT, has emerged as a novel designer drug, and has been said based on online anecdotal reports to have a dose of 20 to 30 mg orally.

== Partnerships == Pilot uses the lure of celebrities in their marketing, including players from the NRL team, the Cronulla Sharks, for which Pilot is a named sponsor. Mixed martial arts star Jack Della Maddalena and Australian swimmer James Magnussen have also been featured. In 2022, Pilot donated AUD $120,000 to the free phone counselling service, This is a Conversation Starter (TIACS).

Sources: en.wikipedia.org

Frequently asked questions

How does CJC-1295 raise growth hormone levels?

It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.

Why does the DAC form last longer?

The drug affinity complex links the peptide to serum albumin through a covalent bond. The conjugate is too large to be filtered quickly by the kidneys and is shielded from enzymatic breakdown. This extends the apparent half-life from roughly minutes to several days.

What remains uncertain about its effects?

Long-term safety and any clinical benefit are unestablished. Published human data cover small groups over limited periods and focus on hormone levels rather than health outcomes. Whether prolonged elevation of growth hormone and insulin-like growth factor 1 is beneficial or harmful is an open question.

Is CJC-1295 the same as modified GRF(1-29)?

The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.

Network